Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Advaxis (ADXS) and Sensus Healthcare Inc (SRTS).
Advaxis (ADXS)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Hold rating on Advaxis today. The company’s shares closed yesterday at $0.41, close to its 52-week low of $0.18.
Ramakanth said:
“We maintain our Neutral rating of ADXS with no price target due to the significant uncertainties surrounding the company’s core ADXS-HOT programs. (1) clinical; (2) financial; (3) regulatory; (4) commercial; and (5) intellectual property. For definitions and the distribution of analyst ratings, analyst certifications, and other disclosures, please refer to pages 2 – 3 of this report.Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c).”
According to TipRanks.com, Ramakanth has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.3% and a 34.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Collplant Holdings Ltd, Leap Therapeutics Inc, and Tyme Technologies Inc.
Advaxis has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
Sensus Healthcare Inc (SRTS)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sensus Healthcare Inc today and set a price target of $13. The company’s shares closed yesterday at $7.74.
Selvaraju commented:
“Our price target is derived from an EV-to-sales multiple of 8.0x based on comparable companies in the dermatology and medical device sectors and TTM revenue ($1.64/share).”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.6% and a 30.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Sensus Healthcare Inc has an analyst consensus of Hold, with a price target consensus of $7.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
